These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 37105265)
41. Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy. Ben-Ami E; Barysauskas CM; von Mehren M; Heinrich MC; Corless CL; Butrynski JE; Morgan JA; Wagner AJ; Choy E; Yap JT; Van den Abbeele AD; Solomon SM; Fletcher JA; Demetri GD; George S Ann Oncol; 2016 Sep; 27(9):1794-9. PubMed ID: 27371698 [TBL] [Abstract][Full Text] [Related]
42. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Lasota J; Miettinen M Histopathology; 2008 Sep; 53(3):245-66. PubMed ID: 18312355 [TBL] [Abstract][Full Text] [Related]
43. Avapritinib in unresectable or metastatic gastrointestinal stromal tumor with PDGFRA exon 18 mutation: safety and efficacy. Henriques-Abreu M; Serrano C Expert Rev Anticancer Ther; 2021 Oct; 21(10):1081-1088. PubMed ID: 34404327 [TBL] [Abstract][Full Text] [Related]
44. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. Heinrich MC; Corless CL; Demetri GD; Blanke CD; von Mehren M; Joensuu H; McGreevey LS; Chen CJ; Van den Abbeele AD; Druker BJ; Kiese B; Eisenberg B; Roberts PJ; Singer S; Fletcher CD; Silberman S; Dimitrijevic S; Fletcher JA J Clin Oncol; 2003 Dec; 21(23):4342-9. PubMed ID: 14645423 [TBL] [Abstract][Full Text] [Related]
45. Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients. Garner AP; Gozgit JM; Anjum R; Vodala S; Schrock A; Zhou T; Serrano C; Eilers G; Zhu M; Ketzer J; Wardwell S; Ning Y; Song Y; Kohlmann A; Wang F; Clackson T; Heinrich MC; Fletcher JA; Bauer S; Rivera VM Clin Cancer Res; 2014 Nov; 20(22):5745-5755. PubMed ID: 25239608 [TBL] [Abstract][Full Text] [Related]
46. Mutational spectrum and classification of novel mutations in patients with metastatic gastrointestinal stromal tumours. Bombac A; Zakotnik B; Bucic M; Setrajcic Dragos V; Gazic B; Stegel V; Klancar G; Novakovic S Int J Oncol; 2020 Jun; 56(6):1468-1478. PubMed ID: 32236636 [TBL] [Abstract][Full Text] [Related]
47. High-resolution melting analysis is a sensitive diagnostic tool to detect imatinib-resistant and imatinib-sensitive PDGFRA exon 18 mutations in gastrointestinal stromal tumors. Künstlinger H; Binot E; Merkelbach-Bruse S; Huss S; Wardelmann E; Buettner R; Schildhaus HU Hum Pathol; 2014 Mar; 45(3):573-82. PubMed ID: 24444465 [TBL] [Abstract][Full Text] [Related]
48. Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. Heinrich MC; Rankin C; Blanke CD; Demetri GD; Borden EC; Ryan CW; von Mehren M; Blackstein ME; Priebat DA; Tap WD; Maki RG; Corless CL; Fletcher JA; Owzar K; Crowley JJ; Benjamin RS; Baker LH JAMA Oncol; 2017 Jul; 3(7):944-952. PubMed ID: 28196207 [TBL] [Abstract][Full Text] [Related]
50. New Tyrosine Kinase Inhibitors for the Treatment of Gastrointestinal Stromal Tumors. Serrano C; Bauer S Curr Oncol Rep; 2022 Feb; 24(2):151-159. PubMed ID: 35061196 [TBL] [Abstract][Full Text] [Related]
51. Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors. Serrano C; Leal A; Kuang Y; Morgan JA; Barysauskas CM; Phallen J; Triplett O; Mariño-Enríquez A; Wagner AJ; Demetri GD; Velculescu VE; Paweletz CP; Fletcher JA; George S Clin Cancer Res; 2019 Dec; 25(24):7287-7293. PubMed ID: 31471313 [TBL] [Abstract][Full Text] [Related]
52. Detection of KIT and PDGFRA mutations in the plasma of patients with gastrointestinal stromal tumor. Kang G; Bae BN; Sohn BS; Pyo JS; Kang GH; Kim KM Target Oncol; 2015 Dec; 10(4):597-601. PubMed ID: 25735500 [TBL] [Abstract][Full Text] [Related]
53. Kinase mutations and imatinib mesylate response for 64 Taiwanese with advanced GIST: preliminary experience from Chang Gung Memorial Hospital. Yeh CN; Chen TW; Lee HL; Liu YY; Chao TC; Hwang TL; Jan YY; Chen MF Ann Surg Oncol; 2007 Mar; 14(3):1123-8. PubMed ID: 17195905 [TBL] [Abstract][Full Text] [Related]